J.WisdorfM.NiedzielskiL.MaaseM.RuckT.et al (2017)
[4] T.D
Discussion First-generation LXR inverse agonists have demonstrated efficacy in preclinical models for the treatment of metabolic disorders, including dyslipidemia and MASLD 19,28
Their unique properties may suit different patient needs based on metabolic profiles and tolerability
Explore the iLLUMA Range iLLUMA Luna iLLUMA Luna is a specialised under-eye treatment formulated to combat dark circles, puffiness, and fine lines
A proper GLP-1 evaluation should include: A complete medical history and review of current medications BMI and body composition assessment Blood work including metabolic panel, HbA1c, lipid panel, and thyroid function Cardiovascular risk assessment Discussion of realistic expectations, side effect management, and a plan for nutritional support Be cautious of any service that prescribes GLP-1 medications after a brief online questionnaire with no physician review